RxDoctor Payments Data

Edmund Grant, MD

Neurology · Tampa, FLNPI 1992724736

Payments from drug & device makers

$19,450in general payments, 2019–2025

Across 924 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • AbbVie$2K
  • Amgen$1K
  • UCB, Inc.$1K
  • Pfizer$829
  • Biogen$803
  • plus $12K from 54 others

What the payments were for

  • Speaking & faculty fees$2241%
  • Food & beverage$19,20399%
  • Education$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis88$1,824
AbbVie(2 entities)85$1,693
Amgen(2 entities)63$1,373
UCB, Inc.45$1,039
Pfizer55$829
Biogen35$803
Argenx US, Inc.21$788
Neurocrine Biosciences, Inc.34$682
Sanofi30$653
Bristol Myers Squibb28$639
Takeda Pharmaceuticals U.S.A., Inc.20$563
Acadia Pharmaceuticals Inc26$525
Lilly USA, LLC30$512
Adamas Pharmaceuticals, Inc.25$509
Teva Pharmaceuticals USA, Inc.23$491
CSL Behring24$450
Amneal Pharmaceuticals LLC21$405
Lundbeck LLC16$394
Acorda Therapeutics, Inc18$354
Eisai Inc.17$350
Biohaven Pharmaceuticals, Inc.15$330
Johnson & Johnson15$312
Genentech USA, Inc.15$295
Sunovion Pharmaceuticals Inc.15$253
Biohaven Pharmaceutical Holding Company Ltd.10$234
Tanabe Pharma America, Inc.9$202
Upsher-smith Laboratories LLC8$196
EMD Serono, Inc.10$188
Vanda Pharmaceuticals Inc.8$177
SK Life Science, Inc.3$167
Otsuka America Pharmaceutical, Inc.7$164
Avion Pharmaceuticals7$125
Impel Pharmaceuticals Inc.7$123
Sumitomo Pharma America, Inc.8$119
MDD US Operations, LLC6$115
Banner Life Sciences, LLC6$111
Cycle Pharmaceuticals Inc5$101
Merz Pharmaceuticals, LLC5$94
Grifols USA, LLC4$92
Dynasplint Systems Inc.2$92
Aquestive Therapeutics, Inc.4$86
Kyowa Kirin, Inc.4$86
Catalyst Pharmaceuticals, Inc.4$81
Supernus Pharmaceuticals, Inc.6$77
Scilex Pharmaceuticals Inc.3$70
Bausch Health US, LLC3$66
AstraZeneca3$66
Avanir Pharmaceuticals, Inc.3$45
E.r. Squibb & Sons, L.L.C.2$43
Neurelis, Inc.2$40
Zyla Life Sciences, Inc.2$40
Jazz Pharmaceuticals Inc.2$39
Xeris Pharmaceuticals, Inc.1$34
Octapharma USA, Inc.1$29
Mallinckrodt Hospital Products Inc.1$28
Abbott1$24
Arbor Pharmaceuticals, Inc.2$23
Alnylam Pharmaceuticals Inc.1$23
Greenwich Biosciences, Inc.1$22
Medtronic1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,450 in reported general payments places this provider in the 70th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$172,829
Medicare patients
773
Services billed
1,161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 46113$2,103,402
GammakedImmune Globul G/Gly/Iga Avg 4620$244,483
RebifInterferon Beta-1a/Albumin13$144,622
EpidiolexCannabidiol (Cbd)12$102,893
Avonex Pen (4 Pack)Interferon Beta-1a11$89,466
Nurtec OdtRimegepant Sulfate38$62,878
NourianzIstradefylline13$43,277
RytaryCarbidopa/Levodopa27$39,516
AptiomEslicarbazepine Acetate23$36,455
Aimovig AutoinjectorErenumab-Aooe33$36,234
Emgality PenGalcanezumab-Gnlm16$20,779
NamzaricMemantine Hcl/Donepezil Hcl16$16,453
Carbidopa-LevodopaCarbidopa/Levodopa407$14,941
Memantine Hcl418$11,510
Carbamazepine ErCarbamazepine48$8,589

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$92$2,103,402113 claims
EMD Serono, Inc.Rebif$188$144,62213 claims
PfizerNurtec Odt, Dilantin$829$66,26854 claims
Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil, Pyridostigmine Bromide$405$45,840100 claims
Kyowa Kirin, Inc.Nourianz$86$43,27713 claims
Sunovion Pharmaceuticals Inc.Aptiom$253$36,45523 claims
AbbVieNamzaric$1,693$16,45316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,434 neurology providers in Florida.

Other neurology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →